An investigation by the Federal Trade Commission into pharmacy benefit managers revealed PBM favoritism toward their own pharmacies and vast market control, which affects both medication access and affordability, according to the agency’s initial July report.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
